The estimated Net Worth of Martin Brenner is at least 789 千$ dollars as of 1 November 2023. Dr Brenner owns over 4,881 units of iBio Inc stock worth over 346,754$ and over the last 6 years he sold IBIO stock worth over 65,978$. In addition, he makes 375,955$ as Chief Scientific Officer at iBio Inc.
Dr has made over 11 trades of the iBio Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 4,881 units of IBIO stock worth 1,318$ on 1 November 2023.
The largest trade he's ever made was selling 47,020 units of iBio Inc stock on 12 July 2023 worth over 27,742$. On average, Dr trades about 4,037 units every 11 days since 2019. As of 1 November 2023 he still owns at least 182,502 units of iBio Inc stock.
You can see the complete history of Dr Brenner stock trades at the bottom of the page.
Dr. Martin B. Brenner D.V.M., Ph.D. is the Chief Scientific Officer at iBio Inc.
As the Chief Scientific Officer of iBio Inc, the total compensation of Dr D at iBio Inc is 375,955$. There are 4 executives at iBio Inc getting paid more, with Thomas Isett having the highest compensation of 1,784,020$.
Dr D is 49, he's been the Chief Scientific Officer of iBio Inc since . There are 14 older and 1 younger executives at iBio Inc. The oldest executive at iBio Inc is Seymour Flug, 84, who is the Independent Director.
Martin's mailing address filed with the SEC is C/O IBIO, INC., 8800 HSC PARKWAY, , BRYAN, TX, 77807.
Over the last 13 years, insiders at iBio Inc have traded over 99,626,328$ worth of iBio Inc stock and bought 15,716,013 units worth 10,660,994$ . The most active insiders traders include Capital Ltd Portfolio Servi...、Carl Desantis、William D Clark. On average, iBio Inc executives and independent directors trade stock every 98 days with the average trade being worth of 1,893,515$. The most recent stock trade was executed by Martin Brenner on 1 November 2023, trading 4,881 units of IBIO stock currently worth 1,318$.
ibio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory approval and commercial product launch. ibio’s technology platform and facility capabilities are applicable to the development of biotherapeutics, vaccines, diagnostic products, and certain types of medical devices – and often provide significant time and value advantages over traditional approaches. ibio’s lab to launch capabilities assure the most rapid manufacturing support to reach the clinic. ibio’s team is comprised of knowledgeable protein scientists, microbiologists and manufacturing and regulatory experts, all of whom add significant expertise and value throughout the entire process. the same team and facility that produces preclinical and clinical material will be the same team producing your product for market launch; contributing to the seamless scale-up process the ibio technology platform creates.
iBio Inc executives and other stock owners filed with the SEC include: